Darrin M. Beaupre
Ideaya Biosciences (United States)(US)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Liver physiology and pathology, Cancer, Hypoxia, and Metabolism, HER2/EGFR in Cancer Research
Most-Cited Works
- → Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma(2013)1,668 cited
- → Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma(2015)1,102 cited
- → Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results(2015)398 cited
- → Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma(2017)288 cited
- → RASand Leukemia: From Basic Mechanisms to Gene-Directed Therapy(1999)190 cited
- → Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors(2010)159 cited
- → Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open‐label studies(2017)141 cited
- → Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL(2019)132 cited
- → Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion–Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid Leukemia(2006)95 cited
- → Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors(2013)91 cited